PMID- 32875987
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20220531
IS  - 1876-1038 (Electronic)
IS  - 1574-8871 (Linking)
VI  - 16
IP  - 2
DP  - 2021
TI  - A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and 
      Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality 
      Assessment Tools.
PG  - 180-192
LID - 10.2174/1574887115666200902111510 [doi]
AB  - BACKGROUND: We performed a critical overview of published systematic reviews 
      (SRs) of chemotherapy for advanced and locally advanced pancreatic cancer, and 
      evaluated their quality using AMSTAR2 and ROBIS tools. MATERIALS AND METHODS: 
      PubMed and Cochrane Central Library were searched for SRs on 13th June 2020. SRs 
      with meta-analysis which included only randomized controlled trials and that had 
      assessed chemotherapy as one of the treatment arms were included. The outcome 
      measures, which were looked into, were progression-free survival (PFS), overall 
      survival (OS), and adverse events (AEs) of grade 3 or above. Two reviewers 
      independently assessed all the SRs with both ROBIS and AMSTAR2. RESULTS: Out of 
      the 1,879 identified records, 26 SRs were included for the overview. Most SRs had 
      concluded that gemcitabine-based combination regimes, prolonged OS and PFS, but 
      increased the incidence of grade 3-4 toxicities when compared to gemcitabine 
      monotherapy, but survival benefits were not consistent when gemcitabine was 
      combined with molecular targeted agents. As per ROBIS, 24/26 SRs had 'high' risk 
      of bias, with only 1/26 SR having 'low' risk of bias. As per AMSTAR2, 25/26 SRs 
      had 'critically low', and 1/26 SR had 'low' confidence in the results. The study 
      which scored 'low risk of bias' in ROBIS scored 'low confidence in results' in 
      AMSTAR2. The inter- rater reliability for scoring the overall confidence in the 
      SRs with AMSTAR2 and the overall domain in ROBIS was substantial; ROBIS: 
      kappa=0.785, SEM=0.207, p<0.001; AMSTAR2: kappa= 0.649, SEM=0.323, p<0.001. 
      CONCLUSION: Gemcitabine-based combination regimens can prolong OS and PFS but 
      also worsen AEs when compared to gemcitabine monotherapy. The included SRs have 
      an overall low methodological quality and high risk of bias as per AMSTAR2 and 
      ROBIS respectively.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Dang, Amit
AU  - Dang A
AD  - MarksMan Healthcare Communications and KYT Adhere, Hyderabad, Telangana - 500032, 
      India.
FAU - Chidirala, Surendar
AU  - Chidirala S
AD  - MarksMan Healthcare Communications and KYT Adhere, Hyderabad, Telangana - 500032, 
      India.
FAU - Veeranki, Prashanth
AU  - Veeranki P
AD  - MarksMan Healthcare Communications and KYT Adhere, Hyderabad, Telangana - 500032, 
      India.
FAU - Vallish, B N
AU  - Vallish BN
AD  - MarksMan Healthcare Communications and KYT Adhere, Hyderabad, Telangana - 500032, 
      India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Rev Recent Clin Trials
JT  - Reviews on recent clinical trials
JID - 101270873
SB  - IM
MH  - Bias
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Pancreatic Neoplasms/drug therapy
MH  - Reproducibility of Results
MH  - *Systematic Reviews as Topic
OTO - NOTNLM
OT  - AMSTAR2
OT  - ROBIS
OT  - methodological quality
OT  - pancreatic cancer
OT  - risk of bias
OT  - systematic review
EDAT- 2020/09/03 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - RRCT-EPUB-109620 [pii]
AID - 10.2174/1574887115666200902111510 [doi]
PST - ppublish
SO  - Rev Recent Clin Trials. 2021;16(2):180-192. doi: 
      10.2174/1574887115666200902111510.